Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

NCT03115138 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire, Amiens as lead sponsor.

NCT NCT03115138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03115138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Not applicable
Overall status
Terminated
Start date
March 9, 2016
Completion date
November 6, 2017
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, molecular disease